Abstract
This report summarizes the recommendations from a consensus meeting that focused on specific questions regarding the pharmacotherapy of schizophrenia. The issues were selected because there was evidence that experts had recently disagreed about the evidence supporting a particular practice or when there were substantial variations in a clinical practice indicating that there was disagreement among clinicians. The group of experts was able to reach a consensus regarding the evidence base pertaining to the following issues: First generation (FGAs) and second generation (SGAs) antipsychotics as first line agents; the duration of antipsychotic trials; the effectiveness of clozapine and other agents for treatment refractory schizophrenia; risk of tardive dyskinesia on FGAs and SGAs; differences among antipsychotics for different dimensions of psychopathology; and side effect monitoring for various antipsychotics.
Original language | English (US) |
---|---|
Pages (from-to) | 5-16 |
Number of pages | 12 |
Journal | Schizophrenia bulletin |
Volume | 28 |
Issue number | 1 |
DOIs | |
State | Published - 2002 |
Keywords
- Antipsychotics
- Clozapine
- Evidence-based practice
- Schizophrenia
- Tardive dyskinesia
ASJC Scopus subject areas
- Psychiatry and Mental health